Cargando…

An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval

INTRODUCTION: Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia known as torsades de pointes (TdP). Over 40 drugs with both cardiac and non-cardiac indications are associated with increased risk of Td...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorberbaum, Tal, Sampson, Kevin J., Woosley, Raymond L., Kass, Robert S., Tatonetti, Nicholas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835515/
https://www.ncbi.nlm.nih.gov/pubmed/26860921
http://dx.doi.org/10.1007/s40264-016-0393-1
_version_ 1782427617477001216
author Lorberbaum, Tal
Sampson, Kevin J.
Woosley, Raymond L.
Kass, Robert S.
Tatonetti, Nicholas P.
author_facet Lorberbaum, Tal
Sampson, Kevin J.
Woosley, Raymond L.
Kass, Robert S.
Tatonetti, Nicholas P.
author_sort Lorberbaum, Tal
collection PubMed
description INTRODUCTION: Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia known as torsades de pointes (TdP). Over 40 drugs with both cardiac and non-cardiac indications are associated with increased risk of TdP, but drug–drug interactions contributing to LQTS (QT-DDIs) remain poorly characterized. Traditional methods for mining observational healthcare data are poorly equipped to detect QT-DDI signals due to low reporting numbers and lack of direct evidence for LQTS. OBJECTIVE: We hypothesized that LQTS could be identified latently using an adverse event (AE) fingerprint of more commonly reported AEs. We aimed to generate an integrated data science pipeline that addresses current limitations by identifying latent signals for QT-DDIs in the US FDA’s Adverse Event Reporting System (FAERS) and retrospectively validating these predictions using electrocardiogram data in electronic health records (EHRs). METHODS: We trained a model to identify an AE fingerprint for risk of TdP for single drugs and applied this model to drug pair data to predict novel DDIs. In the EHR at Columbia University Medical Center, we compared the QTc intervals of patients prescribed the flagged drug pairs with patients prescribed either drug individually. RESULTS: We created an AE fingerprint consisting of 13 latently detected side effects. This model significantly outperformed a direct evidence control model in the detection of established interactions (p = 1.62E−3) and significantly enriched for validated QT-DDIs in the EHR (p = 0.01). Of 889 pairs flagged in FAERS, eight novel QT-DDIs were significantly associated with prolonged QTc intervals in the EHR and were not due to co-prescribed medications. CONCLUSIONS: Latent signal detection in FAERS validated using the EHR presents an automated and data-driven approach for systematically identifying novel QT-DDIs. The high-confidence hypotheses flagged using this method warrant further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0393-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4835515
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-48355152016-05-04 An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval Lorberbaum, Tal Sampson, Kevin J. Woosley, Raymond L. Kass, Robert S. Tatonetti, Nicholas P. Drug Saf Original Research Article INTRODUCTION: Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia known as torsades de pointes (TdP). Over 40 drugs with both cardiac and non-cardiac indications are associated with increased risk of TdP, but drug–drug interactions contributing to LQTS (QT-DDIs) remain poorly characterized. Traditional methods for mining observational healthcare data are poorly equipped to detect QT-DDI signals due to low reporting numbers and lack of direct evidence for LQTS. OBJECTIVE: We hypothesized that LQTS could be identified latently using an adverse event (AE) fingerprint of more commonly reported AEs. We aimed to generate an integrated data science pipeline that addresses current limitations by identifying latent signals for QT-DDIs in the US FDA’s Adverse Event Reporting System (FAERS) and retrospectively validating these predictions using electrocardiogram data in electronic health records (EHRs). METHODS: We trained a model to identify an AE fingerprint for risk of TdP for single drugs and applied this model to drug pair data to predict novel DDIs. In the EHR at Columbia University Medical Center, we compared the QTc intervals of patients prescribed the flagged drug pairs with patients prescribed either drug individually. RESULTS: We created an AE fingerprint consisting of 13 latently detected side effects. This model significantly outperformed a direct evidence control model in the detection of established interactions (p = 1.62E−3) and significantly enriched for validated QT-DDIs in the EHR (p = 0.01). Of 889 pairs flagged in FAERS, eight novel QT-DDIs were significantly associated with prolonged QTc intervals in the EHR and were not due to co-prescribed medications. CONCLUSIONS: Latent signal detection in FAERS validated using the EHR presents an automated and data-driven approach for systematically identifying novel QT-DDIs. The high-confidence hypotheses flagged using this method warrant further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0393-1) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-02-10 2016 /pmc/articles/PMC4835515/ /pubmed/26860921 http://dx.doi.org/10.1007/s40264-016-0393-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Lorberbaum, Tal
Sampson, Kevin J.
Woosley, Raymond L.
Kass, Robert S.
Tatonetti, Nicholas P.
An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
title An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
title_full An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
title_fullStr An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
title_full_unstemmed An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
title_short An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
title_sort integrative data science pipeline to identify novel drug interactions that prolong the qt interval
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835515/
https://www.ncbi.nlm.nih.gov/pubmed/26860921
http://dx.doi.org/10.1007/s40264-016-0393-1
work_keys_str_mv AT lorberbaumtal anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT sampsonkevinj anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT woosleyraymondl anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT kassroberts anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT tatonettinicholasp anintegrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT lorberbaumtal integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT sampsonkevinj integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT woosleyraymondl integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT kassroberts integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval
AT tatonettinicholasp integrativedatasciencepipelinetoidentifynoveldruginteractionsthatprolongtheqtinterval